End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
27.07 CNY | -1.56% | -0.70% | -27.89% |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- The company appears highly valued given the size of its balance sheet.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
Ratings chart - Surperformance
Sector: Fishing & Farming
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-27.89% | 645M | - | ||
+19.15% | 1.04B | - | C- | |
+22.89% | 879M | C | ||
0.00% | 780M | - | - | |
-11.28% | 380M | - | - | |
+6.39% | 373M | - | - | |
-24.85% | 303M | - | - | |
-1.74% | 297M | C- | ||
-25.23% | 276M | - | - | |
-12.17% | 247M | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 300972 Stock
- Ratings Fujian Wanchen Biotechnology Group Co., Ltd.